Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Collaborative Research and Development Grants

Ryerson University

$148,000.00

2009 The CD36 receptor complex and macrophage drug targets of artherosclerosis 2009

EF 2010-11

Résumé
Despite advances in treatment and prevention, complications of atherosclerosis, including coronary heart disease and stroke, remain the leading cause of mortality in the Western world. Atherosclerosis is now widely regarded as a chronic inflammatory disease of the vascular wall, initiated by the aggregation of modified, usually oxidized, low-density lipoproteins (oxLDL) also called ""bad cholesterol"". Macrophages are thought to be key to the genesis and progression of atherosclerosis. When their surface receptors engage oxLDL deposited onto the subendothelial matrix, macrophages generate inflammatory mediators. Gradually, the macrophages take up and store inordinate amounts of cholesterol, becoming ""foam cells"" that have altered immune responsiveness. These abnormalities lead to the formation of plaque and ultimately to its rupture, which causes the thrombosis responsible for infarction and stroke. Recent results from our laboratories and others indicate that large particles of oxLDL are slowly engulfed by macrophages in a protracted process that stimulate macropages into an abnormal inflamatory response. This abnormality could contribute to the development of a localized chronic inflammatory response. The development of atherosclerosis could be lessened by minimizing subendothelial inflammation, and by preventing the further accumulation of cholesterol in macrophages. This can, in theory, be accomplished by neutralizing the inflammatory reaction of CD36 to oxLDL aggregates that contributes prominently to the development of atherosclerosis. However, under normal circumstances, the accumulation and aggregation of oxLDL is prevented by its active endocytosis and metabolism, a process also mediated by CD36 and other scavenger receptors. A suitable strategy would be to enable macrophages to clear dissolved oxLDL, while minimizing the inflammatory response to the large aggregates of oxLDL in the intima of the arteries. This approach requires the ability to separate the normal endocytic pathway that occurs on the nano particle scale from the inflammatory phagocytic functions of scavenger receptors that occurs on the micro particle scale.
Programme
Collaborative Research and Development Grants
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
386003-2009
Name nom
Marshall, John
Department département
Chemistry and Biology
Organization id
43
Institution établissement
Ryerson University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2010
Competition year année de concours
2009
Award amount
148000
Program id
CRDPJ
Program name en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5407
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Receptors
Research subject fr
Récepteurs
Partie
1
Nb partie
2
Application title
2009 The CD36 receptor complex and macrophage drug targets of artherosclerosis 2009
Keyword
NSERC
Application summary
Despite advances in treatment and prevention, complications of atherosclerosis, including coronary heart disease and stroke, remain the leading cause of mortality in the Western world. Atherosclerosis is now widely regarded as a chronic inflammatory disease of the vascular wall, initiated by the aggregation of modified, usually oxidized, low-density lipoproteins (oxLDL) also called ""bad cholesterol"". Macrophages are thought to be key to the genesis and progression of atherosclerosis. When their surface receptors engage oxLDL deposited onto the subendothelial matrix, macrophages generate inflammatory mediators. Gradually, the macrophages take up and store inordinate amounts of cholesterol, becoming ""foam cells"" that have altered immune responsiveness. These abnormalities lead to the formation of plaque and ultimately to its rupture, which causes the thrombosis responsible for infarction and stroke. Recent results from our laboratories and others indicate that large particles of oxLDL are slowly engulfed by macrophages in a protracted process that stimulate macropages into an abnormal inflamatory response. This abnormality could contribute to the development of a localized chronic inflammatory response. The development of atherosclerosis could be lessened by minimizing subendothelial inflammation, and by preventing the further accumulation of cholesterol in macrophages. This can, in theory, be accomplished by neutralizing the inflammatory reaction of CD36 to oxLDL aggregates that contributes prominently to the development of atherosclerosis. However, under normal circumstances, the accumulation and aggregation of oxLDL is prevented by its active endocytosis and metabolism, a process also mediated by CD36 and other scavenger receptors. A suitable strategy would be to enable macrophages to clear dissolved oxLDL, while minimizing the inflammatory response to the large aggregates of oxLDL in the intima of the arteries. This approach requires the ability to separate the normal endocytic pathway that occurs on the nano particle scale from the inflammatory phagocytic functions of scavenger receptors that occurs on the micro particle scale.